Log in

NASDAQ:CHMAChiasma Stock Price, Forecast & News

$6.12
-0.14 (-2.24 %)
(As of 06/2/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.09
Now: $6.12
$6.36
50-Day Range
$3.99
MA: $5.35
$6.81
52-Week Range
$2.88
Now: $6.12
$9.25
Volume299,749 shs
Average Volume354,315 shs
Market Capitalization$258.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.52
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
Read More
Chiasma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CHMA
CUSIPN/A
Phone617-928-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.04 per share

Profitability

Net Income$-36,320,000.00

Miscellaneous

Employees49
Market Cap$258.66 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive CHMA News and Ratings via Email

Sign-up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter.

Chiasma (NASDAQ:CHMA) Frequently Asked Questions

How has Chiasma's stock been impacted by COVID-19 (Coronavirus)?

Chiasma's stock was trading at $3.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CHMA shares have increased by 56.1% and is now trading at $6.12. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Chiasma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chiasma.

When is Chiasma's next earnings date?

Chiasma is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Chiasma.

How were Chiasma's earnings last quarter?

Chiasma Inc (NASDAQ:CHMA) released its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.05. View Chiasma's earnings history.

What price target have analysts set for CHMA?

5 brokerages have issued 1 year target prices for Chiasma's stock. Their forecasts range from $10.00 to $18.00. On average, they anticipate Chiasma's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 112.4% from the stock's current price. View analysts' price targets for Chiasma.

Has Chiasma been receiving favorable news coverage?

News headlines about CHMA stock have been trending positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Chiasma earned a news sentiment score of 2.6 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutChiasma.

Are investors shorting Chiasma?

Chiasma saw a decline in short interest in April. As of April 30th, there was short interest totaling 1,540,000 shares, a decline of 24.9% from the April 15th total of 2,050,000 shares. Based on an average daily volume of 325,100 shares, the days-to-cover ratio is presently 4.7 days. Currently, 5.0% of the company's stock are short sold. View Chiasma's Current Options Chain.

Who are some of Chiasma's key competitors?

What other stocks do shareholders of Chiasma own?

Who are Chiasma's key executives?

Chiasma's management team includes the following people:
  • Mr. Raj Kannan, CEO & Director (Age 56, Pay $475.78k)
  • Mr. Mark J. Fitzpatrick, Pres (Age 57, Pay $788.3k)
  • Mr. Lee Giguere, VP & Gen. Counsel (Age 40, Pay $134.52k)
  • Dr. William H. Ludlam, Sr. VP of Clinical Devel. & Medical Affairs (Age 55, Pay $520.92k)
  • Mr. Drew Enamait, VP of Fin. & Admin. (Age 46)

When did Chiasma IPO?

(CHMA) raised $76 million in an initial public offering on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

What is Chiasma's stock symbol?

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Who are Chiasma's major shareholders?

Chiasma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.04%), Ikarian Capital LLC (4.91%), Rock Springs Capital Management LP (3.19%), Vivo Capital LLC (3.01%), Stonepine Capital Management LLC (1.76%) and State Street Corp (1.47%). Company insiders that own Chiasma stock include Mark J Fitzpatrick, Roni Mamluk, Scott Minick and William Ludlam. View institutional ownership trends for Chiasma.

Which major investors are selling Chiasma stock?

CHMA stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, WINTON GROUP Ltd, JPMorgan Chase & Co., UBS Group AG, and Deutsche Bank AG. View insider buying and selling activity for Chiasma.

Which major investors are buying Chiasma stock?

CHMA stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Ikarian Capital LLC, Stonepine Capital Management LLC, Rock Springs Capital Management LP, Geode Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Spark Investment Management LLC, and BlackRock Inc.. Company insiders that have bought Chiasma stock in the last two years include Mark J Fitzpatrick, Scott Minick, and William Ludlam. View insider buying and selling activity for Chiasma.

How do I buy shares of Chiasma?

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chiasma's stock price today?

One share of CHMA stock can currently be purchased for approximately $6.12.

How big of a company is Chiasma?

Chiasma has a market capitalization of $258.66 million. The biotechnology company earns $-36,320,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Chiasma employs 49 workers across the globe.

What is Chiasma's official website?

The official website for Chiasma is www.chiasmapharma.com.

How can I contact Chiasma?

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.